Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05036343 · ClinicalTrials.gov registry record · NA
A Study to Assess the Effect of Smart Insulin Pens on Glycemic Control and Diabetes-related Burdens
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT05036343: Completed NA study, sponsored by Mayo Clinic.
NCT05036343 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05036343, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the use of the InPen® for teens and young adults up to age 21 years with type 1 diabetes helps to decrease burden and improve glycemic control.
Primary Outcome
The percentage of time that glucose readings are in goal range (70-180 mg/dL)
Interventions
- DEVICE InPen®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2022-11-30 |
| Phase | NA |
What the finished NCT05036343 record still lists
NCT05036343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which InPen® is the first listed.
NCT05036343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05036343 about?
NCT05036343 is a clinical study titled "A Study to Assess the Effect of Smart Insulin Pens on Glycemic Control and Diabetes-related Burdens". The purpose of this study is to see if the use of the InPen® for teens and young adults up to age 21 years with type 1 diabetes helps to decrease burden and improve glycemic control.
What is the current status of trial NCT05036343?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2021-09-14. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT05036343?
The interventions under investigation include: InPen® (DEVICE).
Who is sponsoring clinical trial NCT05036343?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05036343's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI